Definitive Contract 75N93018C00049
Award Date
9/30/18
Potential Completion Date
9/29/25
Potential Value
$9.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Virovax LLC
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Lawrence, KS 66047, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
17
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...
The federal contract award HHSN272200800039C was a $8,394,390.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Vaxine PTY LTD, a for-profit organization, on September 30, 2008. The contract is part of NIAID's Adjuvant Discovery Program and is for biomedical research services. It has a cost-no-fee pricing type and an ultimate completion date of September 29, 2013. The contract was not set aside for any specific business...
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...
This is a $9,807,060 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Chicago. The contract is for the Vaccine Adjuvant Discovery Program (VADP), which aims to evaluate and develop animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics. This contract is not set-aside and is a cost-type...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...
This federal contract award, valued at $9,189,961.00, was granted to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a for-profit limited liability company based in Switzerland. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, for the Vaccine Adjuvant Discovery Program. This five-year definitive contract, running from September 2024...
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...
This is a $4,937,118.00 fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Institut De Formulation DES Vaccins (CH) SA, a non-profit limited liability company, for the advanced development of a liposome-based saponin-containing adjuvant for use in pan-sarbecovirus vaccines. The contract has an ultimate completion date of September 29, 2028 and was awarded on September 30, 2023 with no set-aside designation...